GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JFL Life Sciences Ltd (NSE:JFLLIFE) » Definitions » EBIT

JFL Life Sciences (NSE:JFLLIFE) EBIT : ₹45.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is JFL Life Sciences EBIT?

JFL Life Sciences's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2024 was ₹45.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹45.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JFL Life Sciences's annualized ROC % for the quarter that ended in Mar. 2024 was 8.21%. JFL Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 22.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. JFL Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.22%.

JFL Life Sciences EBIT Historical Data

The historical data trend for JFL Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JFL Life Sciences EBIT Chart

JFL Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial 16.19 19.74 58.50 50.42 45.43

JFL Life Sciences Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT Get a 7-Day Free Trial 16.19 19.74 58.50 50.42 45.43

Competitive Comparison of JFL Life Sciences's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JFL Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JFL Life Sciences's EV-to-EBIT falls into.


;
;

JFL Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹45.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JFL Life Sciences  (NSE:JFLLIFE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JFL Life Sciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=41.523 * ( 1 - 12.95% )/( (413.241 + 466.917)/ 2 )
=36.1457715/440.079
=8.21 %

where

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=490.573 - 76.739 - ( 0.593 - max(0, 151.213 - 411.403+0.593))
=413.241

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=566.417 - 99.159 - ( 0.341 - max(0, 199.812 - 431.315+0.341))
=466.917

Note: The Operating Income data used here is one times the annual (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

JFL Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=45.431/( ( (71.757 + max(147.352, 0)) + (125.418 + max(64.799, 0)) )/ 2 )
=45.431/( ( 219.109 + 190.217 )/ 2 )
=45.431/204.663
=22.20 %

where Working Capital is:

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54.946 + 127.243 + 58.515) - (76.739 + 0 + 16.613)
=147.352

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(38.297 + 158.333 + 20.865) - (99.159 + 0 + 53.537)
=64.799

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

JFL Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=45.431/629.051
=7.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JFL Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of JFL Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

JFL Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JFL Life Sciences Ltd (NSE:JFLLIFE) » Definitions » EBIT
Comparable Companies
BOM:530317 BOM:524711 BOM:524396 BOM:537253 BOM:524703 BOM:524652 BOM:524314 BOM:543963 BOM:539561 BOM:542248 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Jodhpur Cross Road, 309, Satyam Mall, Opposite Saman Complex, Near Vishweshwar Mahadev Mandir, Settelite, Ahmedabad, GJ, IND, 380015
Website
https://www.jfllifesciences.com
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.

JFL Life Sciences Headlines

No Headlines